Sponsored Content
Novartis Opens Production Facility for Innovative Eye Retina Product in Tyrol
Sponsored Content
The pharmaceutical company Novartis is investing EUR 27.4 million in the Kundl site in Tyrol to produce an active ingredient for a new therapy for wet age-related macular degeneration with 40 employees.

The pharmaceutical company Novartis has announced the start of global production of an innovative retinal drug at its Kundl site in Tyrol.
"This compound is a humanized single-chain antibody fragment that requires cutting-edge expertise to produce. …
or Log In
Sponsored Content
Sponsored Content
Sponsored Content
Fast News Search
Related News
COVID-19 Drug Made in Austria (May 19, 2020)
Pfizer Invests 50 Million Euros in Lower Austria (August 28, 2019)
Sponsored Content
Read More
Featured